Design, synthesis, and activity evaluation of novel multitargeted l ‐tryptophan derivatives with powerful antioxidant activity against Alzheimer's disease
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202300603 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Xianghao Zeng und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Antioxidants, Drug Design, Cholinesterase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Jiangxi University of Chinese Medicine Science and Technology Innovation Team Development Program, Jiangxi Provincial Department of Science and Technology.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a multifactorial neurological disease, and the multitarget directed ligand (MTDL) strategy may be an effective approach to delay its progression. Based on this strategy, 27 derivatives of l ‐tryptophan, 3a‐1–3d‐1 , were designed, synthesized, and evaluated for their biological activity. Among them, IC 50 (inhibitor concentration resulting in 50% inhibitory activity) values of compounds 3a‐18 and 3b‐1 were 0.58 and 0.44 μM for human serum butyrylcholinesterase ( h BuChE), respectively, and both of them exhibited more than 30‐fold selectivity for human serum acetylcholinesterase. Enzyme kinetics studies showed that these two compounds were mixed inhibitors of h BuChE. In addition, these two derivatives possessed extraordinary antioxidant activity in OH radical scavenging and oxygen radical absorption capacity fluorescein assays. Meanwhile, these compounds could also prevent β‐amyloid (Aβ) self‐aggregation and possessed low toxicity on PC12 and AML12 cells. Molecular modeling studies revealed that these two compounds could interact with the choline binding site, acetyl binding site, and peripheral anionic site to exert submicromolar BuChE inhibitory activity. In the vitro blood–brain barrier permeation assay, compounds 3a‐18 and 3b‐1 showed enough blood–brain barrier permeability. In drug‐likeness prediction, compounds 3a‐18 and 3b‐1 showed good gastrointestinal absorption and a low risk of human ether‐a‐go‐go‐related gene toxicity. Therefore, compounds 3a‐18 and 3b‐1 are potential multitarget anti‐AD lead compounds, which could work as powerful antioxidants with submicromolar selective inhibitory activity for h BuChE as well as prevent Aβ self‐aggregation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang, China.
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China.
Förderung
- Jiangxi University of Chinese Medicine Science and Technology Innovation Team Development Program
- Jiangxi Provincial Department of Science and Technology
Zitieren
APA
Zeng, X., Cheng, S., Li, H., Yu, H., Cui, Y., Fang, Y., Yang, S., & Feng, Y. (2024). Design, synthesis, and activity evaluation of novel multitargeted l ‐tryptophan derivatives with powerful antioxidant activity against Alzheimer's disease. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300603
Vancouver
Zeng X, Cheng S, Li H, Yu H, Cui Y, Fang Y, et al. Design, synthesis, and activity evaluation of novel multitargeted l ‐tryptophan derivatives with powerful antioxidant activity against Alzheimer's disease. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300603
BibTeX
@article{Zeng2024,
author = {Zeng, Xianghao and Cheng, Shaobing and Li, Huilan and Yu, Haiyang and Cui, Yushun and Fang, Yuanying and Yang, Shilin and Feng, Yulin},
title = {Design, synthesis, and activity evaluation of novel multitargeted l ‐tryptophan derivatives with powerful antioxidant activity against Alzheimer's disease},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202300603}
}
EUVIMED